Given that the most common oncogenic MAPK pathway alteration in pLGG is the KIAA-BRAF fusion, in which upregulation of tumor activity is paradoxically observed with type I BRAF inhibition, downstream MEKis have been increasingly trialed over the last decade as an alternative agent both in these and other MAPK pathway–mutated tumors. Here, BRAF is linked to neoplasm.